close
close

In the first UK study, Amber Therapeutics’ device reduces seizures by 80%.

Posted on by darion

Oral ganaxolone was recently approved in the UK for the treatment of CDKL5 deficiency syndrome. Sources: SewCreamStudio/Shutterstock.com

The first patient to take part in a University College London (UCL)-sponsored clinical trial of deep brain stimulation (DBS) for epilepsy has had an 80% reduction in the number of seizures he has had each day.

A teenager from Great Britain is taking part in the CADET (Adaptive Deep Brain Stimulation for Epilepsy Trial for Children) pilot study, which uses the Amber Therapeutics DBS device called Picostim with DyNeuMo-1 software.

Oran, who suffers from a rare epilepsy syndrome called Lennox-Gastaut, was the first child in the UK to have the device implanted at Great Ormond Street Hospital (GOSH) in October 2023, when he was 12 years old. The device is mounted on the skull and connected to electrodes deep in the brain to reduce seizures.

Picostim is mounted on the skull instead of traditional DBS devices, which are mounted on the chest. This makes the device more suitable for growing children as the wires are less susceptible to cracking and erosion. Moreover, it does not require surgery and replacement every three to five years as it can be charged via wearable headphones.

Three further patients with Lennox-Gastaut syndrome will now be recruited to the Royal Academy of Engineering-funded CADET pilot project. Study sponsor UCL says 22 patients are expected to take part in the full trial, which is funded by GOSH Charity and LifeArc.

The Picostim DyNeuMo neuromodulation therapy platform was developed by British company Bioinduction, but Amber Therapeutics inherited the device when it acquired the company in September 2023.

Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive advantage.

Company Profile – free sample

You will receive a download email shortly

We are sure of the exceptional quality of our company profiles. However, we want you to make the most beneficial decision for your business, which is why we offer a free sample, which you can download by submitting the form below

By GlobalData







Please visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you guarantee that the email address submitted is your corporate email address.

Martin Tisdall, honorary professor at UCL, said: “Deep brain stimulation brings us closer than ever to stopping seizures in patients who have very limited effective treatment options. We are excited to build the evidence base to demonstrate the ability of deep brain stimulation to treat epilepsy in children and hope this will become a standard treatment we can offer in the coming years.”

DBS devices can attack more than just epilepsy. Earlier this week, Boston Scientific obtained CE mark approval for Vercise Neural Navigator 5 software for use as part of the company’s DBS system for the treatment of Parkinson’s disease.

According to a report by the Medical Intelligence Center GlobalData, the neuromodulation device market in the UK will be worth $234 million by 2030.

GlobalData is the parent company Clinical Research Arena.